Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Part of Cancer

32 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pancreatic Ductal Adenocarcinoma

22 trials tracked for Pancreatic Ductal Adenocarcinoma: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 13 citations.

22Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 14 Phase 1 5 Other / NA 1
  1. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  2. Phase 3 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Completed
  3. Phase 2 BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Completed
  4. Phase 2 Study of Tremelimumab in Patients With Advanced Solid Tumors Completed
  5. Phase 2 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed
  6. Phase 2 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Completed
Show 16 more trials
  1. Phase 2 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed
  2. Phase 2 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed
  3. Phase 2 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Completed
  4. Phase 2 Olaparib in Treating Patients With Stage IV Pancreatic Cancer Completed
  5. Phase 2 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Completed
  6. Phase 2 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Completed
  7. Phase 2 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed
  8. Phase 2 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma Completed
  9. Phase 2 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Completed
  10. Phase 2 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  11. Phase 1 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Completed
  12. Phase 1 Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Completed
  13. Phase 1 A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients Completed
  14. Phase 1 Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Completed
  15. Phase 1 A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Completed
  16. N/A A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pancreatic Ductal Adenocarcinoma: what the trials found

NIS793 in combination with Gemcitabine and Nab-paclitaxel demonstrated a safety profile where 0% of participants experienced dose-limiting toxicities (DLTs) during the first cycle (4 weeks). However, adverse events were reported across various categories, and significant rates of dose interruptions and reductions were observed in this specific combination 1.

Capecitabine was evaluated in a large Phase 3 trial; however, it did not show statistically significant differences in overall survival between cohorts in either the Phase II (p=0.62) or Phase III (p=0.38) analysis settings 6.

Recent results — preliminary, needs further review

  • Paricalcitol (Zemplar) was associated with a significant reduction in serum levels of Carbohydrate Antigen 19-9 (CA19-9) (p=0.001) 2.
  • The NabCG regimen (nab-Paclitaxel + Cisplatin + Gemcitabine) resulted in a statistically significant decrease in CA 19-9 or CA 125 levels (p=0.001) and showed a disease control rate of 19% at 9 weeks 4.
  • Dostarlimab demonstrated a disease control rate of 13% and 5% respectively at 12 weeks 7.

For the clinician treating this condition

  • NIS793 combined with Gemcitabine and Nab-paclitaxel is associated with no dose-limiting toxicities in the first cycle, though it may lead to frequent dose interruptions or reductions 1.
  • Capecitabine did not demonstrate a statistically significant impact on overall survival in Phase III clinical evaluations 6.

AI synthesis of 5 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers
Gastroenterology Sys. Review
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers Fungi may play a role in several types of cancer
This narrative review synthesizes evidence regarding fungal dysbiosis in colorectal cancer, gastric cancer, and pancreatic ductal adenocarci…
New research explores how fungal imbalances in the body might link to colorectal, gastric, and pancreatic cancers.
Frontiers Oct 8, 2026
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
Oncology Meta-analysis
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
Frontiers Sep 19, 2026
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Oncology Guideline
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Frontiers Sep 14, 2026
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Gastroenterology Meta-analysis
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
Sep 1, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Oncology Sys. Review
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Frontiers Aug 27, 2026
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
Allergy & Immunology Sys. Review
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
Frontiers Aug 14, 2026
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Frontiers Jun 24, 2026
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Frontiers May 30, 2026

Research across Cancer

Related studies from across the Cancer family.

Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma
Oncology Meta-analysis
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma New drug combination shows promise for advanced stomach cancer
This meta-analysis of 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma found that zanidatamab combined with chemothe…
A new drug combination shows a 70% response rate for patients with a specific type of advanced stomach cancer, though it carries some risks.
Oct 16, 2026
Individualized treatment planning for synchronous bilateral primary breast cancer is supported by independent lesion characterization
Oncology Sys. Review
Individualized treatment planning for synchronous bilateral primary breast cancer is supported by independent lesion characterization Individualized treatment plans help patients with dual primary breast cancers
This case report and literature review examines 1 case and 7 literature cases of synchronous bilateral primary breast cancer. The authors hi…
Doctors are finding that treating each tumor as a unique case helps patients with cancer in both breasts.
Frontiers Oct 2, 2026
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Frontiers Sep 25, 2026
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma
Pulmonology & Critical Care Sys. Review
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma Lung cancer can mimic common lung diseases in young men
This case report and review of the literature describes a 33-year-old male with gastric adenocarcinoma and pulmonary lymphangitic carcinomat…
A 33-year-old man with a lung condition that looked like a common disease was actually a rare form of cancer.
Frontiers Sep 25, 2026
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Oncology Guideline
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Frontiers Sep 13, 2026
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Oncology Meta-analysis
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
Sep 12, 2026
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
Oncology Meta-analysis
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Sep 6, 2026
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Oncology RCT
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.
Aug 22, 2026
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Frontiers May 24, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
Infectious Disease Sys. Review
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Frontiers May 13, 2026
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
Oncology Sys. Review
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Frontiers May 11, 2026

Questions about Pancreatic Ductal Adenocarcinoma

What is the prevalence of CLDN18.2 expression in patients with pancreatic ductal adenocarcinoma?

About 52% of PDAC patients express CLDN18.2, but prevalence varies by testing method; 27% meet clinical trial positivity criteria.

Full answer →
Can AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods?

Yes, AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods, with radiomics and machine learning showing high sensitivity and specificity.

Full answer →

All Pancreatic Ductal Adenocarcinoma Articles